On October 26, 2026, GLORY SUN LAND (00299.HK) said the Listing Committee decided to cancel its listing under Rule 6.01A(1); absent a review, the last trading day is November 6 and delisting takes effect on November 9.
On October 26, 2026, YUE YUEN IND (00551.HK) issued a profit warning, expecting nine-month profit attributable to owners to fall about 50%-55% from US$278.7 million a year earlier, with manufacturing revenue down 3.8%.
On 26 October 2026, CH AGRI-PROD EX (00149.HK) issued HKD 20 million of 2038 notes under its HKD 1 billion medium term note programme, due 26 October 2038.
On 26 October 2026, ELIFE HLDGS (00223.HK) completed a placing of 277,520,000 shares at HKD 0.1 each, raising net proceeds of about HKD 27.20 million.
On October 26, Hong Kong stocks traded mixed, the Hang Seng Index up 0.51% on turnover of 175.8 billion HKD and southbound net selling of 2.275 billion HKD.
BUTONG GROUP (06090.HK) listed on the Main Board of the Hong Kong Stock Exchange on 23 September 2025 at a final offer price of HKD 71.20. Founder Wang Wei established the Boyan Family Trust and serves as its settlor and protector, while co-founder Shen Ling established the Shen Ling Family Trust and serves as its settlor and protector; the trustee of both trusts is Vistra Trust (Singapore) Pte. Limited of Singapore. The company was included in the Hang Seng Composite Index and added to the Stock Connect eligible securities lists on 9 March 2026.
On Oct 23, HBM Holdings-B (02142.HK) announced that batoclimab injection (Enlida) has been approved by China's NMPA for generalized myasthenia gravis, the company's first approved product, on which it retains tiered royalties in Greater China. Included in the Stock Connect on Sept 7, its southbound stake rose from 2.10% on the first effective day to 13.24% on Oct 23, or 119.81 million shares worth about HK$1.23 billion.
LC HOLDING (02490.HK) fell 0.36% to HKD 4.140 on Oct 26; Liu Family Trust holds shares via Lecang Flourishing; Trident Trust at 32.60%; interim profit up 42.9%.
YIDU TECH (02158.HK) traded at HKD 2.915 intraday on Oct 26, up 1.22%, down 23.1% since its removal from Stock Connect on Sept 7; FY2026 revenue rose 14.6%.
Hong Kong indices fell this week, with the HSI down 4.52% and the HSTECH down 5.76%, while southbound outflows reached HK$17.046 billion over four sessions.
On October 26, 2026, ALPHAMAB-B (09966.HK) announced that Phase I/II results of JSKN033 in cervical cancer after failure of standard treatment were presented at the 2026 ESMO Congress, with an ORR of 41.9% and a median PFS of 7.0 months.
HUA HONG GRACE (01347.HK) fell 4.45% to HKD 64.450; 8-inch wafer capacity will shrink 2.4% in 2026 as AI server power demand surges, and Q3 lands 5 November.
On October 26, 2026, ALPHAMAB-B (09966.HK) announced that Phase III results of Anbenitamab (KN026) in first-line HER2+ breast cancer and second-line or later HER2+ gastric cancer were presented at the 2026 ESMO Congress as LBA oral presentations.
On October 26, 2026, YIDU TECH (02158.HK) said its affiliate won the next-generation big data platform project of The First Affiliated Hospital of Chongqing Medical University, worth about RMB13.29 million.
EXELLAND ROBOT (03231.HK) fell 1.04% to HKD 34.400; Zhejiang service robot output rose 91.0% in Q1-Q3, and Agibot set a Guinness record with 110 robots.
Recent listings fell in the week to October 23, 2026: STAR GROUP ASIA gained 77.49%, MICOT PHARMA-B fell 39.92% and Z.AI led turnover at HK$3.838 billion.
